Results 171 to 180 of about 748,749 (317)

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

open access: yesArthritis &Rheumatology, Accepted Article.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week (W), double‐blind, placebo‐controlled, phase 3 POETYK PsA‐2 study
Philip J. Mease   +20 more
wiley   +1 more source

Causal diagrams, the placebo effect, and the expectation effect

open access: yes, 2013
Eyal Shahar,1 Doron J Shahar2 1Division of Epidemiology and Biostatistics, Mel and Enid Zuckerman College of Public Health, 2Department of Mathematics, College of Science, University of Arizona, Tucson, AZ, USA Abstract: Using causal diagrams, a formal ...
Shahar DJ, Shahar E
core  

Outcomes in progressive pulmonary fibrosis in systemic autoimmune rheumatic diseases: real‐world data from the ILD‐PRO Registry

open access: yesArthritis &Rheumatology, Accepted Article.
Objective We evaluated baseline characteristics, treatment patterns, and outcomes in patients with systemic autoimmune rheumatic disease‐associated progressive pulmonary fibrosis (SARD‐PPF) and evaluated whether outcomes differed by SARD subtype. Methods The ILD‐PRO Registry is a prospective multicenter US registry of patients with PPF.
Sonali J Bracken   +7 more
wiley   +1 more source

The Efficacy of Flickering Glasses as a Placebo in Enhancing Reading Performance in Individuals while assessing their heart rate.

open access: yes
reservedThis study investigates the effectiveness of flickering glasses as a placebo in improving reading skills, while assessing heart rate responses.
ALAIN, GENEVIEVE JULIETTE ANGELA
core  

Abatacept Reduces CD319+ (SLAMF7) Cytotoxic T Cells and Cytokine Production in Systemic Sclerosis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Systemic sclerosis (SSc) is characterized by immune dysregulation and fibrosis. We investigated whether abatacept modulates CD319/SLAMF7‐expressing cytotoxic T cells implicated in diffuse cutaneous SSc. Methods In this ancillary ASSET trial analysis, peripheral blood mononuclear cells from 67 participants were analyzed at baseline and months ...
Mikel Gurrea‐Rubio   +15 more
wiley   +1 more source

The placebo effect in reading: a possible relationship with personality traits

open access: yes
reservedLa ricerca ha avuto lo scopo di verificare se sia possibile rilevare un effetto placebo nelle abilità di lettura e se vi sia una relazione tra l’effetto placebo e i tratti di personalità.
TALARICO, CHIARA
core  

Impact of Dual Interleukin‐17A and Interleukin‐17F Inhibition with Bimekizumab on Inflammatory and Structural Lesions in Axial Spondyloarthritis: MRI and Radiographic Outcomes from the Phase 3 BE MOBILE 1 and 2 Studies and their Open‐Label Extension

open access: yesArthritis &Rheumatology, Accepted Article.
Objectives To evaluate the impact of bimekizumab, a dual IL‐17A and IL‐17F inhibitor, on sacroiliac joint (SIJ) and spine inflammation/structural damage in axSpA using MRIs/radiographs from the phase 3 studies BE MOBILE 1 (nr‐axSpA) and 2 (r‐axSpA) and their open‐label extension (OLE).
Walter P. Maksymowych   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy